Digestive and Liver Disease最新文献_第2页

Comparison of the diagnostic performance of narrow-band imaging endocytoscopy and staining-based endocytoscopy for colorectal lesions. 窄带成像细胞镜与染色细胞镜对结直肠病变诊断价值的比较。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-26 DOI: 10.1016/j.dld.2025.08.012

Mingqing Liu, Ying Li, Jiawei Fan, He Zhu, Fengming Ni, Tantan Ma, Erli Cui, Nan Zhang, Hong Xu

{"title":"Comparison of the diagnostic performance of narrow-band imaging endocytoscopy and staining-based endocytoscopy for colorectal lesions.","authors":"Mingqing Liu, Ying Li, Jiawei Fan, He Zhu, Fengming Ni, Tantan Ma, Erli Cui, Nan Zhang, Hong Xu","doi":"10.1016/j.dld.2025.08.012","DOIUrl":"https://doi.org/10.1016/j.dld.2025.08.012","url":null,"abstract":"Background and aims: Endocytoscopy (EC) enables real-time histopathological evaluation through two modes: narrow-band imaging endocytoscopy (ECNBI) and staining-based endocytoscopy (EC-SB). However, the comparative diagnostic accuracy between ECNBI and EC-SB, and their performance of endoscopists with varying levels of experience remains unclear.Methods: This retrospective study analyzed 565 colorectal lesions from 433 patients. Both expert and non-expert endoscopists evaluated colorectal lesions based on ECNBI and EC-SB images. Sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), and inter- and intra-observer agreement were compared with histopathological diagnoses.Results: The sensitivity, specificity, and accuracy for diagnosing hyperplastic polyps by experts using EC-SB are 93.0 %, 98.0 %, and 97.0 %, which were significantly higher than the results of ECNBI (86.8 %, 96.1 %, and 94.2 %, respectively; P < 0.05 for all). Similarly, for diagnosing adenomas to intramucosal cancers, EC-SB by experts achieved significantly higher sensitivity, specificity and accuracy (93.0 %, 94.8 % and 93.6 %) compared to ECNBI (90.2 %, 90.1 % and 90.2 %, respectively; P < 0.05 for all). In addition, for diagnosing invasive cancers, EC-SB by experts showed significantly higher specificity (98.7 % vs. 96.1 %, P < 0.05).Conclusions: EC-SB demonstrated higher diagnostic accuracy for colorectal lesions among experts, supporting its utility for precise treatment decisions.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on "Environmental enteropathy and inflammatory bowel disease are not mutually exclusive". 评“环境性肠病与炎症性肠病并非相互排斥”。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-26 DOI: 10.1016/j.dld.2025.08.065

Xin Xu

引用次数: 0

Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study. 托法替尼和非戈替尼在溃疡性结肠炎患者中的比较有效性和安全性：一项倾向评分加权队列研究。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-26 DOI: 10.1016/j.dld.2025.07.037

Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Clara De Francesco, Nunzio Belluardo, Emiliano Giangreco, Maria Cappello, Roberto Ajovalasit, Filippo Mocciaro, Barbara Scrivo, Antonino Carlo Privitera, Maria Emanuela Distefano, Alessandro Vitello, Concetta Ferracane, Stefano Muscarella, Raffaele Li Voti, Giuseppe Mistretta, Sara Renna, Angelo Casà, Marco Ventimiglia, Ambrogio Orlando

{"title":"Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study.","authors":"Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Clara De Francesco, Nunzio Belluardo, Emiliano Giangreco, Maria Cappello, Roberto Ajovalasit, Filippo Mocciaro, Barbara Scrivo, Antonino Carlo Privitera, Maria Emanuela Distefano, Alessandro Vitello, Concetta Ferracane, Stefano Muscarella, Raffaele Li Voti, Giuseppe Mistretta, Sara Renna, Angelo Casà, Marco Ventimiglia, Ambrogio Orlando","doi":"10.1016/j.dld.2025.07.037","DOIUrl":"https://doi.org/10.1016/j.dld.2025.07.037","url":null,"abstract":"Background: Janus kinase inhibitors (JAKi), including tofacitinib (TOFA, pan-JAK) and filgotinib (FILGO, selective JAK1), are oral agents approved for moderate-to-severe ulcerative colitis (UC). Head-to-head comparative data in real-world settings are limited.Aim: To compare effectiveness and safety of TOFA and FILGO in patients with UC.Methods: We conducted a multicenter cohort study using data from the Sicilian Network for Inflammatory Bowel Diseases. Consecutive adult UC patients treated with TOFA or FILGO and ≥16 weeks of follow-up were included. Propensity score weighting (IPTW) was used to balance baseline characteristics.Results: 263 patients were included (TOFA: n = 171; FILGO: n = 92). At week 24, steroid-free clinical remission was observed in 58.8 % with TOFA and 44.9 % with FILGO (IPTW-adjusted OR: 1.37; 95 % CI: 0.76-2.49; P = 0.30). Clinical response rates at 24 weeks were 63.6 % for TOFA and 59.0 % for FILGO (IPTW-adjusted OR: 1.13; 95 % CI: 0.62-2.08; P = 0.69). Treatment persistence at 24 weeks was 83.5 % for TOFA vs. 76.4 % for FILGO (HR: 0.78; P = 0.30). Adverse event rates were higher with TOFA (12.7 vs. 5.4 per 100 person-years), though not statistically significant (P = 0.152).Conclusion: TOFA and FILGO demonstrated similarly high effectiveness and persistence in real-world UC patients. Both had acceptable safety profiles.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on "Exosomal CCT3 as a biomarker for diagnosis and immune therapy response in patients diagnosed with hepatocellular carcinoma." 外泌体CCT3作为肝癌患者诊断和免疫治疗反应的生物标志物

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-25 DOI: 10.1016/j.dld.2025.08.063

Fei Cheng, Cun Wang

引用次数: 0

Author's reply: "Enhancing the validity of histologic assessments in UC-IPAA outcomes: A critique". 作者回复：“提高UC-IPAA结果的组织学评估的有效性：一项批评”。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-25 DOI: 10.1016/j.dld.2025.08.009

Roberto Gabbiadini, Alessandro Armuzzi

引用次数: 0

Liver transplantation for intestinal malignancies. 肝脏移植治疗肠道恶性肿瘤。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-25 DOI: 10.1016/j.dld.2025.08.008

Alessandro Vitale, Gabriel Gondolesi, Michele Finotti, Clarissa De Nardi, Chiara Naldini, Edoardo G Giannini, Francesco D'Amico

{"title":"Liver transplantation for intestinal malignancies.","authors":"Alessandro Vitale, Gabriel Gondolesi, Michele Finotti, Clarissa De Nardi, Chiara Naldini, Edoardo G Giannini, Francesco D'Amico","doi":"10.1016/j.dld.2025.08.008","DOIUrl":"https://doi.org/10.1016/j.dld.2025.08.008","url":null,"abstract":"Liver transplantation (LT) is increasingly recognised as a valuable treatment option in carefully selected cases of metastatic intestinal cancers. While traditionally reserved for primary liver tumours such as hepatocellular carcinoma (HCC), recent evidence has broadened the transplant oncology paradigm to include colorectal liver metastases (CRLM) and neuroendocrine liver metastases (NELM). This review explores the evolving indications, patient selection criteria, and clinical outcomes of LT in these contexts, emphasising the need for a conceptual and methodological reassessment. We distinguish between prognostic factors, which are variables independently linked with clinical outcomes, and selection criteria, which determine patient eligibility and transplant prioritisation. This distinction is vital for proper candidate stratification. It emphasises the importance of using overall survival as the primary endpoint in transplant oncology rather than recurrence-free survival, which can be misleading due to early detection bias and competing risks. The idea of \"transplant benefit,\" defined as the survival gain attributable to LT compared to non-transplant strategies, is proposed as a fair and informative measure for ethical allocation. Data from prospective studies, such as SECA I-II and the TransMet trial, offer estimates of benefit in different indications, showing significant variation, from 22.5 months in per-protocol CRLM to around 12 months in NELM. We also examine intention-to-treat versus per-protocol analyses, the impact of dropout and waiting list mortality, and the implications for allocation policy. Finally, we outline future directions, including expansion to unresectable tumours beyond the criteria and borderline resectable tumours within the criteria. In the era of personalised medicine, LT for intestinal malignancies requires careful patient selection, transplant ethics, and collaborative oncologic governance.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Critical methodological considerations in radiomics-based risk stratification of hepatoblastoma. 肝母细胞瘤放射学风险分层的关键方法学考虑。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-25 DOI: 10.1016/j.dld.2025.08.010

Jingyi Li, Xizhuang Gao

引用次数: 0

Comment on "The impact of bacterial infection on the risk of portal vein thrombosis development in patients with cirrhosis: A post-hoc analysis". 对“细菌感染对肝硬化患者门静脉血栓形成风险的影响：事后分析”的评论。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-25 DOI: 10.1016/j.dld.2025.07.029

Sadiq Murtaza Sheriff, Waleed Khan, Muhammad Mahad Riaz

引用次数: 0

Symptom-sign dissociation: Alerting mesenteric vascular crisis. 症状-体征分离：提示肠系膜血管危象。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-25 DOI: 10.1016/j.dld.2025.08.069

Qingyu Ji, Hongliang Li, Gang Li, Ruibo Zhang

引用次数: 0

Comment on "Long-term outcomes of transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome: A multicenter study". 对“经颈静脉肝内门体分流治疗Budd-Chiari综合征的长期疗效：一项多中心研究”的评论。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-08-25 DOI: 10.1016/j.dld.2025.08.064

Jinzhen Huang, Nan He, Zeming Wu

引用次数: 0